Please Wait
Applying Filters...
menu
    • menu
    Polpharma-PSE
    News
    Polpharma's HP API facility is live!

    10 Oct 2024

    // PRESS RELEASE

    Rising Prevalence of Cancer and Its Impact on the HP API Market

    10 Oct 2024

    // PRESS RELEASE

    Addressing Nitrosamine Risks in Pharmaceutical Manufacturing

    10 Oct 2024

    // PRESS RELEASE

    Data Compilation
    #PharmaFlow

    Polpharma API

    Contact Supplier

    Website

    BMWS24

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    https://www.youtube.com/embed/AGXpGWpPkm8
    Menu

    Polpharma

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    Key Products KEY PRODUCTS

    SERVICES

    Key Services KEY SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital content

    Explore the latest content creation from this company

    INTERVIEW #SpeakPharma

    read-more
    read-more
    “Polpharma has invested over €35 million in a new facility to handle HPAPIs”

    “Polpharma has invested over €35 million in a new facility to handle HPAPIs”

    Over the recent years, the market for contract development and manufacturing organizations (CDMOs) has been growing at a fast clip owing to a plethora of factors such as the rising demand for biologics, new trends towards personalized medicines and the need to bring new treatments to the market more quickly. This week, SpeakPharma interviews Dawid Ignatowicz, Head of Key Account Management, CDMO, Polpharma, to know how the Polish drugmaker is growing its CDMO business and some of the inherent advantages it enjoys in this landscape. Of late, there has been an increase in demand for drug substance development and cGMP manufacturing services. How is Polpharma gearing up to meet this demand? In fact, the number of drug developments has increased over the past few years.  This coupled with some lack of capacity in some major European CDMO’s, potentiates good opportunities for companies like Polpharma. Over the last few years, Polpharma has been growing its offer on the CDMO, either by adding new capabilities in research and development and in production or by increasing its manufacturing standards (compliance, EHS, etc.).  Our objective is to support our customers into the different phases of drug development, as such we have adapted our systems to be able to answer their requirements on the different stages – with the ultimate goal of providing a reliable, efficient, and cost-effective service to the customers.  What differentiates Polpharma from other CDMOs? Our major strengths can be referred as: good project management skills (we have a group of experienced people that help the customers), transparency (since the inception of a project we have developed a clear and transparent way of communicating flow with the customer so that we can have full visibility of their project in our site), an ability to listen to our customers (a rather simple requirement, but that seems difficult to find in the market), good process design (more delivery kilos of a product we want to establish a good efficient and cost-effective process) and flexibility (we understand that development projects could have changes on the timelines and the capability to adapt to those changes is critical). Besides the above, we have a positive track record of regulatory approvals coupled with experience and expertise in filing to the FDA. We have positive pre-approval inspection audits (PAIs) that reaffirm our robust quality management system. We are known for efficient management of changes and deviations — we are both open and collaborative and work alongside our clients. Tell us about the range of CDMO projects that Polpharma handles. Owing to our decades-long experience in drug substance development, regulatory filing, and commercial manufacturing, Polpharma can support customers at various phases — from clinical supplies, through validation and launch, up to regular commercial supplies. Manufacturing highly potent APIs comes with several challenges, especially with respect to toxicity and exposure. Are you observing more projects with high toxicity? In order to address the growing demand for the development and manufacture of highly active compounds, we have invested over €35 million in a new facility to handle HPAPIs that will include process and analytical R&D, small-scale cGMP manufacturing suites and quality control (QC) labs. This facility will allow us to handle compounds with an occupational exposure limit (OEL) value down to 10 ng/m3 (or OEB6, i.e. very high contamination).  

    Impressions: 2640

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/polpharma-has-invested-over-35mln-euros-in-a-completely-new-facility-to-handle-hpapis

    #SpeakPharma With Polpharma
    11 Sep 2023
    Share info Share

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/polpharma-party-content-63676.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/polpharma-party-content-1610348510.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate 2023

    read-more

      https://www.pharmacompass.com/pdf/party/content/polpharma-party-content-6571.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    High Potency API 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/polpharma-party-content-85823.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    CDMO Brochure 2023

    read-more

      https://www.pharmacompass.com/pdf/party/content/polpharma-party-content-9537.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Ipochem Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/ipochem-ltd-1511155139.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Ipochem Product List 2022

    read-more

      https://www.pharmacompass.com/pdf/party/content/ipochem-ltd-party-content-1645251020.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    FDA approves record eight biosimilars in H1 2024; okays first interchangeable biosimilars for Eylea

    FDA approves record eight biosimilars in H1 2024; okays first interchangeable biosimilars for Eylea

    Biologics, or complex drugs that are derived from living organisms, have revolutionized treatment of various conditions such as cancer, autoimmune diseases, and chronic illnesses. In 2023, eight out of 10 of the world’s top-selling drugs were biologics, including Merck’s Keytruda, AbbVie’s Humira, and Sanofi’s Dupixent.Due to their high costs, accessibility of biologics has been a challenge. That’s why biosimilars, or game-changing copycats of biologics that provide highly similar yet more affordable alternatives to established biologics, are becoming popular.The first biosimilar — Sandoz’ Zarxio — was approved by the US Food and Drug Administration (FDA) in 2015. Its reference biologic was Amgen’s Neupogen (filgrastim).  Since then, the global market for biosimilars has been growing at an impressive pace — between 2015 and 2020, it grew at a whopping compounded annual growth rate (CAGR) of 78 percent, touching US$ 17.9 billion in size. It is expected to continue growing at a CAGR of 15 percent and reach a size of about US$ 75 billion by 2030.Major biosimilar players include Amgen, Sandoz, Samsung Bioepis, Pfizer, Biocon Biologics, Celltrion, Stada Arzneimittel, Accord Healthcare, Fresenius Kabi, Coherus Biosciences, Apotex, and Sanofi. The increasing demand for biosimilars has propelled growth in contract manufacturing. Some of the leading contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) that manufacture biosimilars are Polpharma Biologics, Catalent, Pfizer CentreOne, Lonza, Boehringer Ingelheim BioXcellence, Thermo Fisher Scientific, WuXi Biologics, and FUJIFILM Diosynth Biotechnologies.Access the Interactive Dashboard for Biosimilar Developments (Free Excel)Amgen, Sandoz top list of ‘approved biosimilars’; FDA okays 8 copycats in H1 2024Over the recent years, regulatory agencies like the FDA and the European Medicines Agency (EMA) have established rigorous approval pathways for biosimilars.Since 2015,  FDA has approved 53 biosimilars, while the EMA has approved 86 biosimilars. Among the US, European and Canadian markets, Amgen and Sandoz are tied in the first place with 13 approved biosimilars each. Samsung Biologics has nine approved biosimilars, followed by Pfizer with eight and Biocon Biologics with seven. In the first half of this year, FDA set a record by approving eight biosimilars — the highest for H1 of any year. EMA has okayed six biosimilars so far in 2024.In 2023, five biosimilars were approved by the FDA with just one being okayed in the first half. The year marked the end of exclusivity for Humira after 20 years, in which it netted a total of US$ 200 billion in sales. AbbVie’s flagship autoimmune drug has a record 10 biosimilars.Johnson & Johnson’s Stelara also lost exclusivity in 2023 and as many as 11 drugmakers hope to bring its biosimilars to the market. Amgen’s Wezlana was the first biosimilar to Stelara, and it was approved as interchangeable by FDA in October last year.Access the Interactive Dashboard for Biosimilar Developments (Free Excel) FDA approves first interchangeable biosimilar for Eylea, cuts regulatory feeDeveloping a biosimilar costs both money and time. According to Pfizer, developing a biosimilar can take five to nine years and cost over US$ 100 million, not including regulatory fees.In October 2023, FDA slashed its fees with the program fee at US$ 177,397, down from US$ 304,162. The application fees for products that require clinical data has been set at US$ 1,018,753, down from US$ 1,746,745. The application fee for products that don’t require clinical data has been set lower — at US$ 509,377 —  down from US$ 873,373 set earlier. This reduction in application fee has propelled demand for contract manufacturing of biosimilars.There has also been a rise in approvals of interchangeable biosimilars this year. Interchangeable biosimilars meet additional requirements and may be substituted for its reference product by a pharmacist without consulting the prescriber. This year saw FDA approve the first interchangeable biosimilars for bone cancer drug denosumab (Prolia and Xgeva) in Jubbonti and Wyost as well as for eculizumab (Soliris) in Bkemv.In May, FDA approved the first interchangeable biosimilars for eye drug aflibercept (Eylea) in Opuviz and Yesafili. Other biosimilars approved in 2024 include Simlandi for adalimumab (Humira), Tyenne for tocilizumab (Actemra), Selarsdi for ustekinumab (Stelara), and Hercessi for trastuzumab (Herceptin).Access the Interactive Dashboard for Biosimilar Developments (Free Excel) Merck’s Keytruda, BMS’ Opdivo, Novartis’ Cosentyx brace for biosimilar competitionHealthcare spending in the US is projected to rise from US$ 4.5 trillion in 2022 to US$ 6 trillion by 2027. While biologics involve just two percent of prescriptions, they account for 46 percent of all pharmaceutical spending. In 2022, US$ 252 billion was spent on biologics.Biosimilar-related savings in 2023 were estimated to be US$ 9.4 billion in the US and € 10 billion (US$ 10.68 billion) in Europe. With expensive and widely used drugs like AbbVie’s Humira, J&J’s Stelara, and Regeneron’s Eylea coming under competition, US savings are projected to reach US$ 181 billion through 2027. Between 2026 and 2032, about 39 blockbusters are set to lose exclusivity in the US and Europe. Merck’s Keytruda (pembrolizumab) was the world’s top-selling drug last year, generating US$ 25 billion in sales. Its patent is set to expire in 2028 with sales expected to drop 19 percent to US$ 27.4 billion in 2029 from US$ 33.7 billion the previous year. Samsung Bioepis and Amgen initiated phase 3 trials of pembrolizumab in April and May of this year, respectively.Opdivo (nivolumab), belonging to the same class of drugs, competes with Keytruda and is also set to lose patent protection in 2028. It hauled in US$ 10 billion in total global sales in 2023 for Bristol Myers Squibb. The key patents of Novartis’ Cosentyx (secukinumab) are set to expire between 2025 and 2026. Cosentyx saw sales of US$ 5 billion in 2023. Taizhou Mabtech Pharmaceutical and Bio-Thera Solutions are conducting phase 3 trials of secukinumab.Access the Interactive Dashboard for Biosimilar Developments (Free Excel) Our viewWith over 2 billion people worldwide unable to access life-saving medicines, biosimilars hold the key to healthcare accessibility. In 2023, a record 13 biosimilars were launched in the market — the highest for a single year. And this included nine much-anticipated biosimilars to AbbVie’s Humira.  In April this year, FDA announced a Biosimilars Action Plan to streamline the development of biosimilars. With a sharp focus on biosimilars, we expect more records to be broken in the near term. New launches of biosimilars to drugs like J&J’s Stelara, Regeneron’s Eylea and Merck’s Keytruda will surely help in creating new records.
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 2290

    https://www.pharmacompass.com/radio-compass-blog/fda-approves-record-eight-biosimilars-in-h1-2024-okays-first-interchangeable-biosimilars-for-eylea

    #PharmaFlow by PHARMACOMPASS
    27 Jun 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Polpharma's HP API facility is live!
    Polpharma's HP API facility is live!

    10 Oct 2024

    // PRESS RELEASE

    https://www.api.polpharma.com/articles/polpharmas-hp-api-facility-is-live

    PRESS RELEASE
    10 Oct 2024
    Share Share
    Rising Prevalence of Cancer and Its Impact on the HP API Market
    Rising Prevalence of Cancer and Its Impact on the HP API Market

    10 Oct 2024

    // PRESS RELEASE

    https://www.api.polpharma.com/articles/rising-prevalence-of-cancer-and-its-impact-on-the-hp-api-market

    PRESS RELEASE
    10 Oct 2024
    Share Share
    Addressing Nitrosamine Risks in Pharmaceutical Manufacturing
    Addressing Nitrosamine Risks in Pharmaceutical Manufacturing

    10 Oct 2024

    // PRESS RELEASE

    https://www.api.polpharma.com/articles/addressing-nitrosamine-risks-in-pharmaceutical-manufacturing

    PRESS RELEASE
    10 Oct 2024
    Share Share
    Polpharma acquires Ziołolek
    Polpharma acquires Ziołolek

    01 Oct 2024

    // PRESS RELEASE

    https://polpharma.pl/en/polpharma-acquires-ziololek/

    PRESS RELEASE
    01 Oct 2024
    Share Share
    Polpharma & MSN Lab Announce Strategic Distribution Partnership
    Polpharma & MSN Lab Announce Strategic Distribution Partnership

    23 Sep 2024

    // PRESS RELEASE

    https://polpharma.pl/en/polpharma-and-msn-laboratories-announce-strategic-distribution-partnership/

    PRESS RELEASE
    23 Sep 2024
    Share Share
    Polpharma’s strategic investment in HPAPI facility, the first of this kind in Poland
    Polpharma’s strategic investment in HPAPI facility, the first of this kind in Poland

    12 Sep 2024

    // PRESS RELEASE

    https://www.api.polpharma.com/news/polpharmas-strategic-investment-in-hpapi-facility-the-first-of-this-kind-in-poland/

    PRESS RELEASE
    12 Sep 2024
    Share Share
    Contact Polpharma and get a quotation

    Polpharma is a supplier offers 69 products (APIs, Excipients or Intermediates).

    Find a price of Acetazolamide bulk with DMF, CEP, JDMF offered by Polpharma

    Find a price of Alendronate Sodium bulk with DMF, CEP, JDMF offered by Polpharma

    Find a price of Baclofen bulk with DMF, CEP, JDMF offered by Polpharma

    Find a price of Etodolac bulk with DMF, CEP, JDMF offered by Polpharma

    Find a price of Hydrochlorothiazide bulk with DMF, CEP, JDMF offered by Polpharma

    Find a price of Ibandronate Sodium bulk with DMF, CEP, JDMF offered by Polpharma

    Find a price of Lamotrigine bulk with DMF, CEP, JDMF offered by Polpharma

    Find a price of Risedronate Sodium bulk with DMF, CEP, JDMF offered by Polpharma

    Find a price of Sildenafil Citrate bulk with DMF, CEP, JDMF offered by Polpharma

    Find a price of Tadalafil bulk with DMF, CEP, JDMF offered by Polpharma

    Find a price of Vardenafil Hydrochloride bulk with DMF, CEP, JDMF offered by Polpharma

    Find a price of Zoledronic Acid bulk with DMF, CEP, JDMF offered by Polpharma

    Find a price of Aripiprazole bulk with DMF, CEP offered by Polpharma

    Find a price of Carbamazepine bulk with DMF, CEP offered by Polpharma

    Find a price of Carvedilol bulk with DMF, CEP offered by Polpharma

    Find a price of Dapagliflozin bulk with DMF, JDMF offered by Polpharma

    Find a price of Pentoxifylline bulk with DMF, CEP offered by Polpharma

    Find a price of Rivaroxaban bulk with DMF, CEP offered by Polpharma

    Find a price of Sodium Salicylate bulk with DMF, JDMF offered by Polpharma

    Find a price of Ticagrelor bulk with DMF, CEP offered by Polpharma

    Find a price of Apixaban bulk with DMF offered by Polpharma

    Find a price of Apremilast bulk with DMF offered by Polpharma

    Find a price of Aripiprazole bulk with DMF offered by Polpharma

    Find a price of Aripiprazole Lauroxil bulk with DMF offered by Polpharma

    Find a price of Avanafil bulk with DMF offered by Polpharma

    Find a price of Brexpiprazole bulk with DMF offered by Polpharma

    Find a price of Carbamazepine bulk with CEP offered by Polpharma

    Find a price of Carvedilol Phosphate bulk with DMF offered by Polpharma

    Find a price of Dapagliflozin Propanediol Monohydrate bulk with DMF offered by Polpharma

    Find a price of Empagliflozin bulk with DMF offered by Polpharma

    Find a price of Enzalutamide bulk with DMF offered by Polpharma

    Find a price of Ibandronate Sodium bulk with CEP offered by Polpharma

    Find a price of Isavuconazonium Sulfate bulk with DMF offered by Polpharma

    Find a price of Linagliptin bulk with DMF offered by Polpharma

    Find a price of Molsidomine bulk with CEP offered by Polpharma

    Find a price of Oxcarbazepine bulk with DMF offered by Polpharma

    Find a price of Palbociclib bulk with DMF offered by Polpharma

    Find a price of Pimavanserin Tartrate bulk with DMF offered by Polpharma

    Find a price of Piracetam bulk with CEP offered by Polpharma

    Find a price of Sacubitril-Valsartan bulk with DMF offered by Polpharma

    Find a price of Safinamide Mesylate bulk with DMF offered by Polpharma

    Find a price of Sildenafil Citrate bulk with CEP offered by Polpharma

    Find a price of Sitagliptin Hydrochloride bulk with DMF offered by Polpharma

    Find a price of Solifenacin Succinate bulk with CEP offered by Polpharma

    Find a price of Sulfiram bulk with CEP offered by Polpharma

    Find a price of Tolterodine Tartrate bulk with CEP offered by Polpharma

    Find a price of Topiramate bulk with DMF offered by Polpharma

    Find a price of Xylometazoline Hydrochloride bulk with CEP offered by Polpharma

    Find a price of Abemaciclib bulk offered by Polpharma

    Find a price of Acenocoumarol bulk offered by Polpharma

    Find a price of Aniracetam bulk offered by Polpharma

    Find a price of Antazoline HCl bulk offered by Polpharma

    Find a price of Antazoline Mesylate bulk offered by Polpharma

    Find a price of Antazoline Sulfate bulk offered by Polpharma

    Find a price of Baricitinib bulk offered by Polpharma

    Find a price of Carfilzomib bulk offered by Polpharma

    Find a price of Clemastine bulk offered by Polpharma

    Find a price of Clopamide bulk offered by Polpharma

    Find a price of Denotivir bulk offered by Polpharma

    Find a price of Elagolix Sodium bulk offered by Polpharma

    Find a price of Naldemedine bulk offered by Polpharma

    Find a price of Nefopam Hydrochloride bulk offered by Polpharma

    Find a price of Opipramol Dihydrochloride bulk offered by Polpharma

    Find a price of Ozanimod Hydrochloride bulk offered by Polpharma

    Find a price of Phenyl Salicylate bulk offered by Polpharma

    Find a price of Salicylamide bulk offered by Polpharma

    Find a price of Trametinib bulk offered by Polpharma

    Find a price of Undecylenic acid monoethanolamide bulk offered by Polpharma

    Find a price of Vismodegib bulk offered by Polpharma